Early combination therapy of COVID-19 in high-risk patients

• DOI: 10.1007/s15010-023-02125-5
• Publication Date: 2023-11-29T01:01:51Z
• Authors: Hans Martin Orth; Charlotte Flasshove; Moritz Berger; Tessa Hattenhauer; Kaja D. Biederbick; Rebekka Mispelbaum; Uwe Klein; Jannik Stemler; Matthis Fisahn; Anna D. Doleschall; Ben-Niklas Baermann; Eva Koenigshausen; Olga Tselikmann; Alexander Killer; Clara de Angelis; Smaranda Gliga; Johannes Stegbauer; Nikolai Spuck; Gerda Silling; Jürgen K. Rockstroh; Christian P. Stra...; Peter Brossart; Jens P. Panse; Björn-Erik Ole Je...; Tom Luedde; Christoph Boesecke; Annkristin Heine; Oliver A. Cornely; Malte B. Monin
• Keywords: 2019-20 coronavirus outbreak; Pandemic

Prolonged shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been observed in immunocompromised hosts. Early monotherapy with direct-acting antivirals or monoclonal antibodies, as recommended by the international guidelines, does not prevent this certainty. Dual therapies may therefore have a synergistic effect.